ALK-inhibitors as a novel potential therapy for proteasome inhibitor-resistant multiple myeloma

被引：0
|
作者：
Besse, Lenka
Besse, Andrej
Kraus, Marianne
Jasik, Matej
Slaby, Ondrej
Driessen, Christoph
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2851
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2851
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Novel combination therapy for treating proteasome inhibitor-resistant multiple myeloma
    Kim, Byung-Gyu
    Choi, Sung Hee
    Huong Nguyen
    Liang, Fu-Sen
    Kim, Seong-Jin
    Letterio, John
    Huang, Alex
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma
    Mendez-Lopez, Max Alberto
    Besse, Andrej
    Totu, Tiberiu
    Kraus, Marianne
    Janssen, Anthonius P. A.
    Buljan, Marija
    Van der Stelt, Mario
    Besse, Lenka
    Driessen, Christoph
    BLOOD, 2023, 142
  • [3] Novel proteasome inhibitors as therapy in multiple myeloma
    Chauhan, D.
    Hideshima, T.
    Mitsiades, C.
    Richardson, F.
    Munshi, N.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 25 - 26
  • [4] Approved ALK-inhibitors induce cytotoxicity in multiple myeloma by targeting the ER-resident kinase LTK and overcome resistance to proteasome inhibitors
    Besse, A.
    Kraus, M.
    Schjesvold, F. H.
    Munthe, L. A.
    Farhan, H.
    Besse, L.
    Driessen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 99 - 99
  • [5] Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
    Bennett, Melissa K.
    Li, Manjun
    Tea, Melinda N.
    Pitman, Melissa R.
    Toubia, John
    Wang, Paul P-S
    Anderson, Dovile
    Creek, Darren J.
    Orlowski, Robert Z.
    Gliddon, Briony L.
    Powell, Jason A.
    Wallington-Beddoe, Craig T.
    Pitson, Stuart M.
    NEOPLASIA, 2022, 24 (01): : 1 - 11
  • [6] Proteasome inhibitor therapy in multiple myeloma
    Chauhan, D
    Hideshima, T
    Mitsiades, C
    Richardson, P
    Anderson, KC
    MOLECULAR CANCER THERAPEUTICS, 2005, 4 (04) : 686 - 692
  • [7] Novel proteasome inhibitors in multiple myeloma
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2006, 6 (05): : 370 - 372
  • [8] Ancistrocladinium A Induces Apoptosis in Proteasome Inhibitor-Resistant Multiple Myeloma Cells: A Promising Therapeutic Agent Candidate
    Bruennert, Daniela
    Seupel, Raina
    Goyal, Pankaj
    Bach, Matthias
    Schraud, Heike
    Kirner, Stefanie
    Koester, Eva
    Feineis, Doris
    Bargou, Ralf C.
    Schlosser, Andreas
    Bringmann, Gerhard
    Chatterjee, Manik
    PHARMACEUTICALS, 2023, 16 (08)
  • [9] Combining the Ras Inhibitor Salirasib and Proteasome, Inhibitors: A Potential Treatment for Multiple Myeloma.
    Yaari-Stark, Shira
    Nevo-Caspi, Yael
    Jacob-Hircsh, Jasmine
    Rechavi, Gideon
    Nagler, Arnon
    Kloog, Yoel
    BLOOD, 2010, 116 (21) : 756 - 757
  • [10] High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma
    Stessman, H. A. F.
    Lulla, A.
    Xia, T.
    Mitra, A.
    Harding, T.
    Mansoor, A.
    Myers, C. L.
    Van Ness, B. G.
    Dolloff, N. G.
    LEUKEMIA, 2014, 28 (11) : 2263 - 2267
12345